Acumen Pharmaceuticals
Acumen Pharmaceuticals develops monoclonal antibodies targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment.
8-KSep 18Latest SEC filing, period to Sep 17
Aug 12Latest story
August 2026
Sign inSign inAcumen Pharmaceuticals develops monoclonal antibodies targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment.